Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 4/20 | 0.43 |
| ▸ | CDC42BPA | Q5VT25 | 4/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.40 |
| ▸ | FLT4 | P35916 | 2/20 | 0.40 |
| ▸ | FES | P07332 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12077354 | 1.00 | ROCK1 (0.43) | ROCK1CDC42BPAAURKBCHEK2MAPKAPK2 | |
| SCHEMBL12077957 | 0.88 | NAMPT (0.53) | ROCK1CDC42BPAAURKBCHEK2MAPKAPK2 | |
| SCHEMBL12077914 | 0.88 | NAMPT (0.53) | ROCK1CDC42BPAAURKBCHEK2MAPKAPK2 | |
| SCHEMBL12077917 | 0.88 | NAMPT (0.53) | ROCK1CDC42BPAAURKBCHEK2MAPKAPK2 | |
| SCHEMBL12092499 | 0.87 | ROCK1 (0.42) | ROCK1CDC42BPAAURKBCHEK2MAPKAPK2 | |
| SCHEMBL12092500 | 0.87 | ROCK1 (0.42) | ROCK1CDC42BPAAURKBCHEK2MAPKAPK2 | |
| SCHEMBL13045693 | 0.78 | ROCK1 (0.46) | ROCK1CDC42BPAAURKBCHEK2MAPKAPK2 | |
| SCHEMBL1835907 | 0.77 | MAPKAPK2 (0.53) | ROCK1CDC42BPAAURKBCHEK2MAPKAPK2 | |
| SCHEMBL16626153 | 0.76 | NAMPT (0.38) | ROCK2NAMPTKEAP1NFE2L2 | |
| SCHEMBL4366215 | 0.75 | ROCK1 (0.55) | ROCK1CDC42BPAAURKBCHEK2MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006426-B2 | Squaric acid derivatives as inhibitors of the nicotinamide | TOPOTARGET A/S (DK) | 2015-04-14 | — | — | US | disclosed |
| US-9006426-B2 | Squaric acid derivatives as inhibitors of the nicotinamide | TOPOTARGET A/S (DK) | 2015-04-14 | — | — | US | disclosed |
| US-9006426-B2 | Squaric acid derivatives as inhibitors of the nicotinamide | TOPOTARGET A/S (DK) | 2015-04-14 | — | — | US | disclosed |
| US-20120225847-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | ONXEO DK, BRANCH OF ONXEO S.A., FRANCE (DK) | 2012-09-06 | — | — | US | disclosed |
| US-20120225847-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | ONXEO DK, BRANCH OF ONXEO S.A., FRANCE (DK) | 2012-09-06 | — | — | US | disclosed |
| US-20120225847-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | ONXEO DK, BRANCH OF ONXEO S.A., FRANCE (DK) | 2012-09-06 | — | — | US | disclosed |
| EP-2318369-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | TopoTarget A/S (DK) | 2011-05-11 | — | — | EP | disclosed |
| WO-2009156421-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | TOPOTARGET A/S (DK) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009156421-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | TOPOTARGET A/S (DK) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225847-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | SUCNR1, NAMPT, NAPRT | ROCK1 2540/4885CDC42BPA 4164/4885AURKB 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.